Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen Looks at Former J&J Exec as Potential CEO Candidate
BioSpace
Mon, 10/10/22 - 07:00 pm
Biogen
Pharma CEOs
JNJ
Mathai Mammen
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Biogen, Denali begin late-stage testing of Parkinson’s drug
BioPharma Dive
Mon, 10/3/22 - 11:28 pm
Biogen
Denali Therapeutics
Parkinson's Disease
clinical trials
BIIB122
Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage
Medical Marketing and Media
Thu, 09/29/22 - 10:23 am
Medicare
Medicare Part B
Biogen
Aduhelm
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Lecanemab can; now the wait for details begins
EP Vantage
Wed, 09/28/22 - 11:45 am
Biogen
Eisai
lecanemab
clinical trials
Alzheimer's disease
A Biotech Breakthrough Means Big Gains for These 2 Stocks
Motley Fool
Wed, 09/28/22 - 11:02 am
Eli Lilly
Biogen
Alzheimer's disease
lecanemab
donanemab
Biogen/Eisai Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
Stat
Wed, 09/28/22 - 12:04 am
Biogen
Eisai
Alzheimer's disease
clinical trials
lecanemab
Biogen pays $900M to settle wide-ranging physician kickback claims
Endpoints
Tue, 09/27/22 - 10:40 am
Biogen
whistleblowers
whistleblower lawsuits
legal
kickbacks
Biogen bolsters case for ALS drug under FDA review with new published data
MedCity News
Fri, 09/23/22 - 10:36 am
Biogen
ALS
FDA
tofersen
Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on
Fierce Pharma
Wed, 09/21/22 - 07:53 pm
Biogen
Aduhelm
Massachusetts
Boston
real estate
Cambridge
Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar
Endpoints
Tue, 09/20/22 - 08:36 pm
Biogen
Novartis
Sandoz
biosimilars
Tysabri
MS
multiple sclerosis
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
Mon, 09/19/22 - 09:53 pm
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise
BioSpace
Fri, 09/9/22 - 11:07 am
Biogen
litifilimab
lupus
systemic lupus erythematosus
monoclonal antibodies
clinical trials
Drug makers leave the pain behind
EP Vantage
Fri, 08/26/22 - 10:26 am
painkillers
Acadia
Eli Lilly
Ampio Pharmaceuticals
Aptinyx
Eliem Therapeutics
Vertanical
Teva Pharamceutical
Regeneron
Vivozon
Vertex Pharmaceuticals
Biogen
Aduhelm’s loss is a win for value-based drug pricing
MedCity News
Thu, 08/11/22 - 10:39 am
Biogen
Aduhelm
value-based pricing
drug pricing
Alzheimer's disease
Amid $1B downsizing, Biogen lists Boston-area office space for sublease
Fierce Pharma
Wed, 08/10/22 - 10:51 am
Biogen
Boston
Cambridge MA
July Brings Layoffs, Job Creation for the Life Sciences
BioSpace
Wed, 08/3/22 - 09:32 pm
layoffs
hirings
Astellas
Pfizer
Eikon Therapeutics
Bayer
Avadel Pharma
Heron Therapeutics
Adverum Biotechnologies
Biogen
Eisai
X4 Pharmaceuticals
Assembly Biosciences
Biogen deflects claims it misled shareholders about Aduhelm's success
Fierce Pharma
Mon, 08/1/22 - 10:27 am
Biogen
Aduhelm
Alzheimer's disease
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Wed, 07/27/22 - 10:58 am
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »